Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2)

Clinical trial NCT06813365 · RECRUITING

Trial details

NCT number: NCT06813365
Sponsor: Dizal Pharmaceuticals
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Nonsmall-cell Lung Cancer

Start date: 2024-06-12
Primary completion: 2026-12-30
Enrollment: 190

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.